Claims
- 1. An isolated antibody that can recognize an immunogenic peptide or epitope from the Mp58 mannoprotein of C. albicans selected from the group consisting of a pH-sensitive carbohydrate moiety, and peptides having the amino acid sequence as set forth in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.
- 2. The antibody of claim 1 which is a monoclonal antibody.
- 3. The antibody of claim 1 which is a polyclonal antibody.
- 4. The monoclonal antibody according to claim 2 wherein the antibody is of a type selected from the group consisting of chimeric, murine, humanized and human monoclonal antibodies.
- 5. The monoclonal antibody according to claim 2 wherein the antibody is a single chain monoclonal antibody.
- 6. The antibody according to claim 1, wherein said antibody prevents a Candidal infection in a human or animal.
- 7. The antibody according to claim 1, wherein said antibody inhibits binding of Candida microorganisms to an extracellular matrix adhesin.
- 8. The antibody according to claim 1, wherein said antibody is suitable for parenteral, oral, intranasal, subcutaneous, aerosolized or intravenous administration in a human or animal.
- 9. Isolated antisera containing an antibody according to claim 1.
- 10. A diagnostic kit comprising an antibody according to claim 1 and means for detecting binding by that antibody.
- 11. A diagnostic kit according to claim 10 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.
- 12. A method of treating or preventing a infection of a microorganism from the genus Candida comprising administering to a human or animal patient an effective amount of an antibody according to claim 1.
- 13. A pharmaceutical composition for treating or preventing a candidal infection comprising an effective amount of the antibody of claim 1 and a pharmaceutically acceptable vehicle, carrier or excipient.
- 14. A monoclonal antibody that can recognize the mp58 mannoprotein of C. albicans, a carbohydrate epitope from mp58 or a peptide epitope from mp58 selected from the group consisting of SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.
- 15. The monoclonal antibody according to claim 14 wherein the antibody is selected from the group consisting of monoclonal antibodies 1H4, 3H3, and 3C2.
- 16. The monoclonal antibody according to claim 14, wherein said antibody can treat or prevent an infection caused by a member of the genus Candida in a human or animal.
- 17. Isolated antisera containing an antibody according to claim 14.
- 18. A diagnostic kit comprising an antibody according to claim 14 and means for detecting binding by that antibody.
- 19. A diagnostic kit according to claim 18 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.
- 20. A method of treating or preventing a infection of a microorganism from the genus Candida comprising administering to a human or animal patient an effective amount of an antibody according to claim 14.
- 21. A pharmaceutical composition for treating or preventing a candidal infection comprising an effective amount of the monoclonal antibody of claim 14 and a pharmaceutically acceptable vehicle, carrier or excipient.
- 22. A method of diagnosing an infection caused by a microorganism from the genus Candida comprising introducing an antibody according to claim 14 into a sample of biological material suspected of having a candidal infection and determining if said antibody binds with antigens in said sample.
- 23. An isolated immunogenic protein or peptide from C. albicans comprising a protein or peptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.
- 24. A method of eliciting an immunogenic reaction in a human or animal comprising administering to said human or animal an immunologically effective amount of an isolated protein or peptide according to claim 23.
- 25. A vaccine comprising an immunogenic amount of the isolated protein or peptide according to claim 23 and a pharmaceutically acceptable vehicle, carrier or excipient.
- 26. A pharmaceutical composition comprising the isolated protein or peptide according to claim 23 and a suitable vehicle, carrier or excipient.
- 27. An isolated nucleic acid sequence coding for a protein or peptide according to claim 23.
- 28. A method of assaying for the presence of antigens from a Candida microorganism in a biological sample suspected of containing said antigens comprising (a) simultaneously forming a mixture comprising the sample, together with an antibody according to claim 14 in the form of either a solid phase immobilized antibody bound to a solid phase immunoadsorbent or a soluble labeled antibody; (b) incubating the mixture formed in step (a) for a time and under conditions sufficient to allow antigen in the sample to bind to either said immobilized or said labeled antibody; and (c) detecting either labeled antibody bound to the solid phase immunoadsorbent or detecting the labeled soluble antibody.
- 29. A method according to claim 28 further including a step of washing, stirring, shaking or filtering.
- 30. A method of monitoring the level of Candidal antigens or antibodies recognizing said antigens in a human or animal patient suspected of containing said antigens or antibodies comprising (a) obtaining a biological sample from said human or animal patient; (b) introducing into said sample either a determinable level of an antibody according to claim 14 when it is desired to monitor levels of Candidal antigens, or introducing a determinable level of a Candidal protein or peptide selected from the group consisting of SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11 when it is desired to monitor levels of antibodies recognizing said antigens, (c) incubating the sample when combined with the antigens or antibodies for a time and under conditions sufficient to allow the antigens and antibodies to bind; and (d) monitoring the level of antigens or antibodies in the sample by determining the level of antigen-antibody binding which will reflect the level of either Candidal antigens, or antibodies thereto, which are in the sample.
- 31. A monoclonal antibody that can recognize the pH-sensitive carbohydrate epitope from the mp58 mannoprotein.
- 32. The monoclonal antibody according to claim 31 wherein the antibody is of a type selected from the group consisting of chimeric, murine, humanized, human, and single chain monoclonal antibodies.
- 33. The monoclonal antibody according to claim 31 wherein the antibody is mAb 1H4.
- 34. The monoclonal antibody according to claim 31, wherein said antibody can treat or prevent an infection caused by a member of the genus Candida in a human or animal.
- 35. Isolated antisera containing an antibody according to claim 31.
- 36. A diagnostic kit comprising an antibody according to claim 31 and means for detecting binding by that antibody.
- 37. A diagnostic kit according to claim 36 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.
- 38. A method of treating or preventing a infection of a microorganism from the genus Candida comprising administering to a human or animal patient an effective amount of an antibody according to claim 31.
- 39. A pharmaceutical composition for treating or preventing a candidal infection comprising an effective amount of the monoclonal antibody of claim 31 and a pharmaceutically acceptable vehicle, carrier or excipient.
- 40. A method of diagnosing an infection caused by a microorganism from the genus Candida comprising introducing an antibody according to claim 31 into a sample of biological material suspected of having a candidal infection and determining if said antibody binds with antigens in said sample.
- 41. An isolated immunogenic carbohydrate moiety comprising the pH-sensitive carbohydrate epitope from the C. albicans mp58 mannoprotein which is recognized by monoclonal antibody mp58.
- 42. A method of detecting the presence of antibodies against the mp58 mannoprotein of Candida albicans comprising introducing an isolated carbohydrate moiety according to claim 41 into a sample of biological material suspected of having antibodies to mp58 determining if the carbohydrate moiety binds with antibodies in said sample.
- 43. A diagnostic kit comprising an isolated carbohydrate moiety according to claim 41 and means for detecting binding by an antibody to said moiety.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of U.S. provisional applications Ser. No. 60/446,560, filed Feb. 12, 2003, and Ser. No. 60/373,324, filed Apr. 18, 2002.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60446560 |
Feb 2003 |
US |
|
60373324 |
Apr 2002 |
US |